Stem Cells have the remarkable potential to develop into many different cell types in the body, ultimately serving as a repair system for the body by dividing and replenishing other cells without any limitations. New research shows that transplanted stem cells to the brain or spine canal can migrate to the damaged areas and assume the function of neurons. This could potentially increase the success rate of therapies for Alzheimer’s Disease, Parkinson’s Disease, spinal cord injury, stroke, Cerebral palsy, ALS disease and other neurodegenerative diseases. The therapeutic use of stem cells also strengthens treatment success for chronic infections, immune-related diseases, and other related conditions.
Most of the patients who have received Stem cells after successful Lyme treatments and/or during remission have benefitted substantially. Due to this success, it is important to properly schedule the right time for applications, the correct number of cells as well as the specific type of cells needed to regenerate the affected organ and its functions. Actively infected candidates will lower their success rate of regeneration with Stem cells due to the high TNF, IL, Cytokines and other inflammatory activity that will inhibit Stem cell differentiation and maturation.
The current types of Mesenchymal cells we use are purified Allogenic living Stem cells from different lineage and origin (bone marrow, adipose cells and Wharton’s jelly), which can be specified for specific tissues depending the necessity of each case: neural, muscular, condroital, epithelium, bone, renal, hepatic, cardiac, vascular, pulmonary and epidermal. From those cases, the results vary from patient to patient depending on age, underlying illness and previous treatments. Consequently, what makes any treatment successful will be the multi-factorial issues such as underlying disease, compatibility of Stem cells, oxidative stress of patient and both genetic and metabolic response. In some cases, the best manner in which we can prepare the candidate and the continuity of application of Stem cells is by factor of change, meaning that some repetitive cases are more successful than single application cases. However, this is not always the case, and success rate should be discussed with doctor per case.
Autologous Stem cells are also synthesized in our labs as they are also a choice for Lyme cases; however due to the patient’s high levels of cellular oxidation stress and the level of infection in their peripheral and bone marrow areas, there could potentially be less viability in Stem cells for differentiation. Overall, there has been better success in Lyme cases where Allogenic differentiated Stem cells are combined with autologous Stem cells, not combined with Stem cell peptides infused via IV.
Stem cell examples of successful treatments done at our facilities:
Autologous Stem cell transplant to the brain, more than 100 million cells
Autologous Stem cell transplant to the spine, more than 200 million cells
Autologous Immature Stem cell transplant intravascular, more than 100 million cells
Autologous Mature Stem cell transplant intravascular, more than 100 million cells
Autologous Immature Stem cell transplant intra-arterial, more than 100 million cells
Autologous Mature Stem cell transplant intra-arterial, more than 100 million cells
Autologous Stem cell transplant to affected organ (liver, kydney, heart, lungs, bones) more than 100 million cells
Autologous Immature Stem cell transplant intra-articular (joints) more than 100 million cells
Autologous Mature Stem cell transplant intra-articular (joints) more than 100 million cells
Autologous Stem cell transplant intervertebral (disc herniation) more than 100 million cells
Allogenic Stem cell transplant to the brain, more than 80 million cells
Allogenic Stem cell transplant to the spine, more than 160 million cells
Allogenic Stem cell transplant intravascular, more than 80 million cells
Allogenic Stem cell transplant intra-arterial, more than 80 million cells
Allogenic Stem cell transplant to affected organ (liver, kydney, heart, lungs, bones) more than 80 million cells
Allogenic Stem cell transplant intra-articular (joints) more than 80 million cells
Allogenic Stem cell transplant intervertebral (disc herniation) more than 80 million cells
Thymosin Alpha 1
Thymosin Beta 4
CJC + Ipamorellin 1
PT 141 1
Cold Laser Therapy
Cold Laser Therapy is a nerve, muscle and joint regenerative aid for people suffering from musculoskeletal conditions, neuropathy and injuries, such as: carpal tunnel syndrome (CTS); fibromyalgia, osteoarthritis; rheumatoid arthritis; temporomandibular joint (TMJ) disorders; wound healing; Complex Relapsing Pain Syndrome (CRPS); MMN; peripheral neuropathy; denervation; and physical injury. It has been shown to improve nerve growth and circulation up to 40% more than conventional therapy. We suggest that if you or someone you know is suffering from such conditions to consider trying CLT combined with C.M.P. FORTE and cerebrolysin peptide, thus achieving a much higher success rate. It’s easy, simple, painless and anti-inflammatory.
Treatments involve handheld devices used by the clinician and are often the size of a flashlight. The laser is placed directly over the injured area for 30 seconds to several minutes, depending on the size of the area being treated and the dose provided by the cold laser unit. During this time, the non-thermal photons of light that are emitted from the laser pass through the skins layers (the dermis, epidermis, and the subcutaneous tissue or tissue fat under the skin). This light has the ability to penetrate 2 to 5 centimeters below the skin at 90mw and 830 nm.
Information coming soon. For immediate inquiries, please contact us.